mProX™ Human CCR4 Stable Cell Line

Product Information

Target Protein

CCR4

Target Family

Chemokine Family

Target Protein Species

Human

Host Cell Type

MDA-MB-231;CHO-K1;HEK293

Target Classification

GPCR Cell Lines

Target Research Area

Immunology Research

Related Diseases

Mycosis Fungoides;Peripheral T-Cell Lymphoma

Gene ID

Human: 1233

UniProt ID

Human: P51679

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CCR4, or C-C chemokine receptor type 4, is another protein that has been extensively researched in the scientific community. This receptor is known for its role in mediating immune responses, particularly in the context of T cell subsets. One of the notable findings related to CCR4 is its expression in various T cell subsets, including regulatory T cells (Tregs). The therapeutic potential of targeting CCR4 has been explored in various studies. For instance, Mogamulizumab, an anti-CCR4 monoclonal antibody, has shown clinical activity against adult T-cell leukemia/lymphoma. Another study emphasized the significance of the CCL2-CCR4 axis in suppressing cell migration in head and neck squamous cell carcinoma. Furthermore, research has indicated that anti-CCR4 treatment can deplete regulatory T cells, presenting a promising therapeutic approach for advanced prostate cancer. In essence, the application of CCR4 in scientific research offers valuable insights into immune regulation and potential therapeutic interventions in various diseases.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human CCR4 Stable Cell Line (S01YF-0923-PY37). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Donna (Verified Customer)

How can resistance to CCR4-targeting therapies develop? Jul 24 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

Resistance can develop due to various mechanisms, including the loss of CCR4 expression or mutations that alter the receptor's function. Continuous monitoring and validation are essential when using CCR4-targeting therapies. Jul 24 2023

chat Charles (Verified Customer)

Are there any known interactions or pathways associated with CCR4 in stabilized cell lines? Jun 04 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

CCR4 can interact with various ligands and intracellular signaling molecules, playing a role in T cell migration and other immune responses. Jun 04 2022

Published Data

Fig.1 CCR4 promotes the tumor growth in vivo.

Volumes of CCR4 overexpressing tumors were larger than those in wild type tumors and vector control tumors (P<0.01). All the primary tumors were evaluated by pathologic examinatio. The result showed that microvessel density was significantly increased in tumors formed by CCR4-overexpressing cells.

Ref: Li, Ji-Yu, et al. "The chemokine receptor CCR4 promotes tumor growth and lung metastasis in breast cancer." Breast cancer research and treatment 131 (2012): 837-848.

Pubmed: 21479551

DOI: 10.1007/s10549-011-1502-6

Research Highlights

Zacharias ZR, Houtman JCD. "OMIP-099: 31-color spectral flow cytometry panel to investigate the steady-state ." Cytometry. Part A : the journal of the International Society for Analytical , 2023.
The authors have developed a 31-color panel for the characterization of T cells in human peripheral blood (Table 1). The panel was optimized using cryopreserved peripheral blood mononuclear cells (PBMC) and includes markers (CD45RA, CD45RO, CCR7, CD95) for the identification of subsets (such as naive, T(EM), T(CM), T(EMRA), and T(SCM)) of CD4, CD8, and gammadelta T cells. Additionally, the panel includes markers (CD27, CD28) for differentiation status, markers (CD11a, CD49d, CD38, HLA-DR, CD56, CD39) for activation/antigen experience status, markers (PD-1, TIM-3) for co-inhibitory marker expression, and markers (CXCR3, CXCR5, CCR4, CCR6, Foxp3, CD25, CD127) for CD4 T helper subsets. This optimized panel allows for a comprehensive assessment of the steady-state phenotype of T cells in human peripheral blood.
Pubmed: 37814476 DOI: 10.1002/cyto.a.24799

Ou HL, et al. "[Hydnocarpin inhibits malignant progression of triple negative breast cancer via ." Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese , 2023.
The study aimed to investigate the effects of HC on the migration and invasion of TNBC cells (MDA-MB-231 and MDA-MB-436) through various assays. Results indicated that HC inhibited proliferation, colony formation, invasion, and EMT in TNBC cells and decreased the levels of YAP and YAP downstream targets (CTGF and Cyr61) at both protein and mRNA levels. Overexpression of YAP reversed the inhibitory effects of HC on proliferation, migration, and invasion. HC promoted YAP degradation through the proteasome pathway and increased its ubiquitination level. Further experiments revealed direct binding between HC, YAP, and CNOT4. Thus, HC inhibited TNBC progression through CNOT4-mediated degradation and ubiquitination of YAP.
Pubmed: 37802875 DOI: 10.19540/j.cnki.cjcmm.20230510.706